Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCSAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Oculis Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Oculis Holding's regulatory disclosures and financial reporting.
Oculis Holding reported a 2025 net loss of CHF 99.0 million (vs. CHF 85.8 million in 2024) as it stepped up investment in its late‑stage pipeline. Cash, cash equivalents and short‑term investments rose to CHF 213.0 million, or $268.7 million, helped by $210.0 million of equity financings in February and November 2025, giving a cash runway into 2029.
During 2025, the company obtained FDA Breakthrough Therapy designation for Privosegtor in optic neuritis and initiated the PIONEER‑1 registrational trial. Both Phase 3 DIAMOND trials of OCS‑01 in diabetic macular edema enrolled over 800 patients, with topline data expected in Q2 2026 and a possible NDA in Q4 2026 if results are positive. Oculis also launched the genotype‑based PREDICT‑1 registrational trial of Licaminlimab in dry eye disease, with topline results targeted for Q4 2026.
Oculis Holding AG filing reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/23/2025, with an aggregate market value of $442,500 based on the notice. The filing shows 43,662,402 shares outstanding. The shares were acquired on 03/02/2023 as issuance of earnout shares from the issuer and fully paid on that date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller is unaware of any undisclosed material adverse information.